LadRx (STU:CX5) Change In Payables And Accrued Expense : €0.16 Mil (TTM As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is LadRx Change In Payables And Accrued Expense?

LadRx's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was €0.14 Mil. It means LadRx's Accounts Payable & Accrued Expense increased by €0.14 Mil from Sep. 2023 to Dec. 2023 .

LadRx's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €0.16 Mil. It means LadRx's Accounts Payable & Accrued Expense increased by €0.16 Mil from Dec. 2022 to Dec. 2023 .

LadRx Change In Payables And Accrued Expense Historical Data

The historical data trend for LadRx's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Change In Payables And Accrued Expense Chart

LadRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.08

0.18

0.83

-1.46

0.16

LadRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-0.07	0.16	-0.09	-0.05	0.14

LadRx Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.16 Mil.

LadRx Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of LadRx's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

LadRx (STU:CX5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

LADX:USA

Address

11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049

Website

https://www.ladrxcorp.com

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines